The assay of voriconazole in plasma from patients with hepatic insufficiency by UPLC-MS/MS
10.12206/j.issn.1006-0111.202008017
- VernacularTitle:用UPLC-MS/MS法测定肝功能不全患者血浆中伏立康唑的浓度
- Author:
Linlin LIU
1
;
Hongtao SONG
1
;
Jia YAN
1
Author Information
1. No.900 Hospital of Joint Logistics Support Force of the PLA, Fuzhou 350025, China.
- Keywords:
UPLC-MS/MS;
voriconazole;
hepatic insufficiency;
therapeutic drug monitoring
- From:
Journal of Pharmaceutical Practice
2021;39(2):160-163
- CountryChina
- Language:Chinese
-
Abstract:
Objective To establish an UPLC-MS/MS method of voriconazole assay in human plasma for clinical therapeutic drug monitoring. Methods The plasma samples were treated with methanol to precipitate protein and the supernatants were assayed by UPLC-MS/MS. The chromatographic column was InertSustain C18 HP (3.0 mm×100 mm, 3 μm) with the mobile phase of water and acetonitrile solution (15:85) at 35 ℃ and 0.3 ml/min flow rate. ESI was used for Mass Spectrum in positive ion MRM mode with target ions m/z: 350.9/282.2(voriconazole) and m/z: 307.0/238.0(fluconazole). Results The linear range of voriconazole was 0.1–20 μg/ml (r=0.999 5）. The lower limit of quantitation was 0.1 μg/ml. The extraction recovery was higher than 90%. RSDs of inter-day and intra-day were all lower than 10%. The plasma concentrations measured by this method were in the range of 0.97 to 18.7 μg/ml from 10 patients with hepatic insufficiency who were treated with voriconazole. Conclusion The established method was fast, accurate and sensitive。It can be applied for the therapeutic drug monitoring of voriconazole，and provided a good base for rationalized medication treatment in patients with hepatic insufficiency.
